As one-third of newly diagnosed AML patients are characterized by the presence of FLT3 mutations, which is also overexpressed on the majority of AML blasts [197], FLT3 inhibitors (FLT3i) such as midostaurin, gilteritinib and sorafenib have been implemented into clinical practice. This evidence concerns the gene FLT3 and acute myeloid leukemia.